Adjuvant topical dorzolamide or timolol with intravitreal bevacizumab for diabetic macular edema: A double-blind randomized controlled trial
Diabetic macular edema (DME) is a leading cause of visual impairment among diabetic patients, primarily managed with intravitreal anti-VEGF agents such as bevacizumab. However, the exploration of adjunctive therapies to enhance treatment outcomes remains an area of ongoing research. This study inves...
Na minha lista:
| Principais autores: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Caspian Medical Futurology
2024-03-01
|
| Colecção: | Journal of Current Biomedical Reports |
| Assuntos: | |
| Acesso em linha: | https://jcbior.com/index.php/JCBioR/article/view/279 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|